What are checkpoint inhibitors and how do they help with Melanoma

Understanding Checkpoint Inhibitors for Melanoma

Checkpoint inhibitors are an important type of immunotherapy—treatments that help your own immune system fight cancer. Let me explain how they work and why they're particularly valuable for melanoma.

How Your Immune System Normally Works

Your body has immune cells called T cells (specifically "killer T cells" or cytotoxic T cells) that patrol your body looking for threats—including cancer cells. These T cells are designed to recognize and destroy abnormal cells.

The Problem Cancer Creates

Here's where melanoma gets clever: Cancer cells have special proteins on their surface called immune checkpoint proteins. One of the most important is called PD-L1. When this protein binds to a matching protein on your T cells (called PD-1), it's like the cancer cell is putting on a "disguise" that tells your T cells: "Don't attack me—I'm safe."

This binding essentially puts the brakes on your immune system, allowing the cancer to hide and grow unchecked.

How Checkpoint Inhibitors Work

Checkpoint inhibitors are drugs that block this binding process. By blocking the connection between PD-L1 and PD-1, these medications remove the "off switch" that cancer uses to hide from your immune system. This frees your T cells to recognize and attack the melanoma cells.

According to the NCCN Guidelines for Patients: Melanoma (2025), checkpoint inhibitors work by "blocking the proteins from binding, which then frees the T cells to kill the tumor cells."

Common Checkpoint Inhibitors Used for Melanoma

The NCCN Guidelines identify two primary checkpoint inhibitors used to treat melanoma:

• Pembrolizumab (Keytruda)
• Nivolumab (Opdivo)

There's also a newer subcutaneous (under-the-skin) form available: nivolumab combined with hyaluronidase-nvhy (Opdivo Qvantig), which can be injected every 2-4 weeks instead of requiring IV infusions.

How They're Administered

According to NCCN Guidelines, checkpoint inhibitors are typically:

• Slowly injected into a vein (IV infusion) taking 30-60 minutes for the full dose
• Given every few weeks (the exact schedule depends on which drug is used)
• Now available in a subcutaneous injection form as an alternative to IV infusions

When Are They Used?

Checkpoint inhibitors are used at different stages of melanoma treatment:

• After surgery (adjuvant therapy) to reduce the risk of recurrence
• Before surgery (neoadjuvant therapy) to shrink tumors
• As primary treatment for advanced or metastatic melanoma
• For recurrent melanoma depending on your specific situation

Important Context

The NCCN Guidelines emphasize that checkpoint inhibitors represent a significant advance in melanoma treatment. However, which specific treatment is right for you depends on many factors your oncology team will consider—including your melanoma stage, whether you have specific genetic mutations (like BRAF), your overall health, and your previous treatments.

Questions to Ask Your Care Team

If checkpoint inhibitors are being considered for your care:

1. Am I a candidate for checkpoint inhibitor therapy? What factors support this recommendation?
2. Which checkpoint inhibitor do you recommend for my specific situation—pembrolizumab, nivolumab, or another option?
3. Will I receive IV infusions or the newer subcutaneous injection form? What's the schedule?
4. How will we monitor whether the treatment is working? What tests will you use?
5. What side effects should I expect, and how will we manage them?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.